Elios Vision announces ELIOS registration in the United Kingdom
The technology uses excimer laser energy to create microscopic openings in the trabecular meshwork to re-establish the natural flow of aqueous.
An innovative technology used to treat glaucoma at the same time as cataract surgery (ELIOS) is now registered for use in the United Kingdom.
The technology uses excimer laser energy to create microscopic openings in the trabecular meshwork to re-establish the natural flow of aqueous.
It does not require an implant and provides long-lasting results that may free patients and their doctors from the demands of drop therapy, said the company in a prepared statement.
“Multiple clinical studies across Europe have demonstrated that ELIOS has a strong efficacy and safety profile, with significant advantages over other forms of microinvasive glaucoma surgery (MIGS),” said Elliot Friedman, chief executive officer of Elios Vision.
“Cataract surgery is an opportune time to improve glaucoma control and especially to reduce the medication burden in those on chronic therapy. ELIOS’ excimer laser technology removes TM tissue with minimal surgical trauma, minimizing the healing response and avoiding the need to place an implant. This makes ELIOS a very attractive option at the time of cataract surgery,” said Prof Keith Barton, Consultant Ophthalmologist, Moorfields Eye Hospital, London.
